Background.
CRP and family history independently associate with future cardiovascular events and have been incorporated into risk prediction models for women (the Reynolds Risk Score for women). However, no cardiovascular risk prediction algorithm incorporating these variables currently exists for men.
Methods.
Among 10,724 initially healthy American non-diabetic men who were followed prospectively for incident cardiovascular events over a median period of 10.8 years, we developed a cardiovascular risk prediction model that included hsCRP and parental history of myocardial infarction before age 60 years, and compared model fit, discrimination, and reclassification to prediction models limited to age, blood pressure, smoking, total cholesterol, and high-density lipoprotein cholesterol.
Results.
1,294 cardiovascular events accrued during study follow-up. Predictive models incorporating hsCRP and parental history (the Reynolds Risk Score for men) had better global fit (P<0.001), a superior (lower) Bayes Information Criterion (BIC)(23008 vs 23048), and larger C-indexes (0.708 vs 0.699, P < 0.001) than did predictive models without these variables. For the endpoint of all cardiovascular events, the Reynolds Risk Score for men reclassified 17.8 percent of the study population into higher- or lower-risk categories with markedly improved accuracy among those reclassified. In models based on the ATP-III preferred endpoint of coronary heart disease and limited to men not taking lipid-lowering therapy, 16.7 percent of the study population were reclassified to higher- or lower-risk groups, again with significantly improved global fit (P<0.001), smaller BIC (13870 vs 13891), larger C-index (0.714 vs 0.704, P < 0.001), and almost perfect accuracy among those reclassified (99.9 percent). For this model, NRI was 8.4 percent and CNRI 15.8 percent (both P-values < 0.001).
Conclusion.
We developed an improved global risk prediction algorithm for men incorporating hsCRP and parental history that should allow better targeting of preventive therapies to maximize benefit while minimizing toxicity and cost.